Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 97 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Psychedelic Clear all
Completed Early Phase 1 Interventional

Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer

NCT04522804
View directory record Official record
Conditions
Cancer
Interventions
Psilocybin
Drug
Lead sponsor
University of Utah
Other
Eligibility
25 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 19, 2026, 5:27 AM EDT
Completed Phase 1 Interventional Results available

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.

NCT03356483
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Psilocybin (0.25mg/kg), Niacin (250mg)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 5:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Role of Serotonin in Acute and Subacute MDMA Effects

NCT00838305
View directory record Official record
Conditions
MDMA Mechanism of Action
Interventions
MDMA and citalopram, Placebo
Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 19, 2026, 5:27 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics

NCT06624137
View directory record Official record
Conditions
OCD, Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Healthy Volunteer, Migraine, PTSD, PTSD - Post Traumatic Stress Disorder, Addiction, Tobacco Use Disorder, Obsessive Compulsive Disorder (OCD), Opioid Use Disorder
Interventions
Serotonergic Psychedelic, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Hamden, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 19, 2026, 5:27 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

NCT04982796
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Psilocybin, Treatment-as-usual
Drug · Behavioral
Lead sponsor
Portland VA Research Foundation, Inc
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Vancouver, Washington
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 19, 2026, 5:27 AM EDT
Recruiting Phase 1 Interventional

Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine

NCT04161066
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin with facilitated counseling
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 19, 2026, 5:27 AM EDT
Not yet recruiting Phase 2 Interventional

Study of Psilocybin Under Anesthesia Controlled by EEG

NCT07479550
View directory record Official record
Conditions
Major Depression
Interventions
Psilocybin (Usona Institute), Propofol, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
25 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 19, 2026, 5:27 AM EDT
Completed Phase 2 Interventional

Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder

NCT05554094
View directory record Official record
Conditions
PTSD, Stress Disorders, Traumatic, Stress Disorders, Post-Traumatic, Trauma and Stressor Related Disorders, Mental Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 5:27 AM EDT
Recruiting Not applicable Interventional

Feasibility of Incorporating a Standardized Substance Use Measure With Linked-Brief Intervention Into Routine Psychosocial Care of Adult Childhood Cancer Survivors

NCT07516301
View directory record Official record
Conditions
Survivors of Childhood Cancer, Substance Use
Interventions
WHO ASSIST v3.1 Screening with Feedback, ASSIST Linked Brief Intervention (10 Step Motivational interviewing (MI)/FRAMES), WHO ASSIST v3.1 Screening (No Feedback)
Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
15 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 19, 2026, 5:27 AM EDT
Active, not recruiting Phase 2 Interventional

PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)

NCT06853912
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), PTSD
Interventions
Psilocybin 25 mg, Maltodextrin (Placebo)
Drug
Lead sponsor
Nathan Brashares Sackett
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 19, 2026, 5:27 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Comparing the Effects of Psilocin and Psilocybin in Healthy Adults

NCT05317689
View directory record Official record
Conditions
Healthy
Interventions
Psilocin, Psilocybin, Sublingual Psilocin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
25 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 19, 2026, 5:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics

NCT05478278
View directory record Official record
Conditions
QTc Interval, Pharmacokinetics
Interventions
Psilocybin, Moxifloxacin, Micro-Crystalline Cellulose
Drug
Lead sponsor
Usona Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 19, 2026, 5:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Psychedelics and Wellness Study (PAWS)

NCT04040582
View directory record Official record
Conditions
Depression, Anxiety, PTSD
Interventions
Not listed
Lead sponsor
WILD 5 Wellness
Other
Eligibility
18 Years to 100 Years
Enrollment
3,234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 19, 2026, 5:27 AM EDT
Recruiting Phase 2 Interventional

Investigation to Understand and Optimize Psilocybin

NCT06512194
View directory record Official record
Conditions
Depression
Interventions
Psilocybin, Transcutaneous Auricular Vagus Nerve Stimulation (taVNS), Sham taVNS
Drug · Device
Lead sponsor
Charles Raison
Other
Eligibility
18 Years to 70 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Edwards, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 19, 2026, 5:27 AM EDT
Recruiting Phase 2 Interventional

State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma

NCT06888128
View directory record Official record
Conditions
PTSD
Interventions
Psilocybin 15mg, Psilocybin 25mg
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 19, 2026, 5:27 AM EDT
Completed Early Phase 1 Interventional Results available

Psilocybin Cancer Anxiety Study

NCT00957359
View directory record Official record
Conditions
Cancer
Interventions
Psilocybin, Niacin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 76 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 19, 2026, 5:27 AM EDT
Active, not recruiting Phase 1 Interventional

Effects of Repeated Psilocybin Dosing in OCD

NCT05370911
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 19, 2026, 5:27 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Psilocybin Microdosing on Cognition, Mood and Quality of Life

NCT07449351
View directory record Official record
Conditions
Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI
Interventions
Psliocybin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 19, 2026, 5:27 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The ENHANCE Study: taVNS and Psilocybin

NCT05866471
View directory record Official record
Conditions
Healthy, Psychedelic Experiences, Vagus Nerve Stimulation
Interventions
Psilocybin, Transcutaneous auricular Vagus Nerve Stimulation (taVNS), Psychosocial Support Alone, Sham taVNS
Drug · Device · Behavioral + 1 more
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 19, 2026, 5:27 AM EDT
Completed Phase 2 Interventional

Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV

NCT06538285
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Ketamine, Psychotherapy
Drug · Behavioral
Lead sponsor
Nicky Mehtani, MD, MPH
Other
Eligibility
18 Years to 69 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francicso, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 19, 2026, 5:27 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Open-Label Psilocybin Study in Transdiagnostic Population

NCT06442423
View directory record Official record
Conditions
Transdiagnostic, Depression - Major Depressive Disorder, Anxiety, PTSD Symptoms, PTSD, Substance Use, Substance Use Disorder (SUD), OCD
Interventions
Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 19, 2026, 5:27 AM EDT
Recruiting Phase 2 Interventional

A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

NCT06820723
View directory record Official record
Conditions
Depression, Anxiety, Major Depressive Disorder
Interventions
CYB003, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 19, 2026, 5:27 AM EDT
Recruiting Phase 2 Interventional

Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial

NCT06405607
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol Dependence, Alcohol Abuse
Interventions
Psilocybin, Ketamine
Drug
Lead sponsor
University of Iowa
Other
Eligibility
21 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 19, 2026, 5:27 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic

NCT04769297
View directory record Official record
Conditions
Acute Stress Disorder
Interventions
Sublingual Micro-Dose Ketamine
Drug
Lead sponsor
Limbic Medical
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Toluca Lake, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 19, 2026, 5:27 AM EDT